查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595629

前列腺癌诊断市场：按测试类型、年龄组和最终用户 - 2025-2030 年全球预测

Prostate Cancer Diagnostics Market by Test Type (Confirmatory Tests, Preliminary Tests), Age Group (Age 55-75, Age <55, Age>75), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年前列腺癌诊断市场价值为12.7亿美元，预计到2024年将达到14.5亿美元，复合年增长率为14.20%，到2030年将达到32.3亿美元。

前列腺癌诊断市场包括用于识别和监测前列腺癌患者的各种测试和技术。这包括 PSA（前列腺特异性抗原）测试和切片检查等传统方法，以及 MRI 和基因组测试等先进程序。从摄护腺癌的盛行率来看，尤其是在人口老化的人群中，对有效诊断工具的需求显而易见，而准确的诊断对于有效的治疗和管理至关重要。治疗方法多种多样，包括早期发现、疾病进展监测和治疗效果评估。最终使用者包括医院、诊断实验室、癌症治疗中心等。

主要市场统计
基准年[2023] 12.7亿美元
预测年份 [2024] 14.5亿美元
预测年份 [2030] 32.3亿美元
复合年增长率（%） 14.20%

市场成长的主要驱动力是前列腺癌盛行率的增加、技术进步以及对该疾病的认识不断提高。个人化医疗和生物标记测试提供了重要的机会，重点是提高诊断准确性和针对患者的治疗计划。将人工智慧整合到诊断工具中也有希望，有可能提高检测率并减少解释时间。为提高诊断工具的敏感度和特异性而进行的研发投资可能会为产业参与者带来显着的好处。值得注意的是，新兴市场的医疗保健基础设施正在开发中，并且存在尚未开发的开拓潜力。

然而，挑战依然存在，例如先进诊断技术的高成本以及欠发达地区缺乏足够的医疗基础设施。此外，标准诊断方法可能会产生误报，可能导致不必要的治疗，这突显出需要更精确和可靠的测试。监管障碍和冗长的核准流程也对市场进入和创新造成了障碍。

专注于非侵入性测试方法的创新，例如液态切片和多参数成像，代表了有希望的研究途径。此外，巨量资料和机器学习用于分析患者资料并执行模式识别，这提供了有助于早期诊断和个人化治疗策略的见解，进一步推动市场成长。为了利用这些机会，公司必须投资于技术进步和策略伙伴关係，以增加市场占有率和影响力。

市场动态：快速发展的前列腺癌诊断市场的关键市场洞察

供需的动态交互作用正在改变前列腺癌诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 人口老化加剧和前列腺癌盛行率增加
    • 癌症诊断技术的进步和政府不断意识提升的倡议
  • 市场限制因素
    • 严格的监管和不断上升的诊断成本
  • 市场机会
    • 基因组学和蛋白​​质组学的製药创新和进步
    • 准确检测前列腺癌的影像学研究和进展
  • 市场挑战
    • 临床试验成功率低

波特五力：驾驭前列腺癌诊断市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对前列腺癌诊断市场的影响

外部宏观环境因素在塑造前列腺癌诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解前列腺癌诊断药物市场的竞争状况

前列腺癌诊断市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 在前列腺癌诊断市场的定位矩阵供应商绩效评估

FPNV定位矩阵是评估前列腺癌诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘前列腺癌诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对前列腺癌诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口老化加剧和前列腺癌发生率增加
      • 加强政府努力改进癌症诊断技术并提高人们对癌症的认识
    • 抑制因素
      • 严格的法规和高昂的诊断成本
    • 机会
      • 基因组学和蛋白​​质组学的製药创新和进步
      • 准确检测前列腺癌的影像学研究和进展
    • 任务
      • 临床试验成功率低
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按测试类型分類的前列腺癌诊断药物市场

  • 确认测试
    • 切片检查
    • PCA3测试
    • 经直肠超音波检查
  • 初步测试

第七章前列腺癌诊断药物市场：依年龄组

  • 年龄55-75岁
  • 年龄55岁以下
  • 年龄>75

第八章前列腺癌诊断市场：依最终用户分类

  • 癌症研究组织
  • 医院相关实验室
  • 独立诊断实验室

第九章美洲前列腺癌诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区摄护腺癌诊断药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的摄护腺癌诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AdvaCare Pharma
  • bioMerieux SA
  • Eurolyser Diagnostica
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Koninklijke Philips NV
  • mdxhealth BV
  • Myriad Genetics, Inc.
  • OPKO Health, Inc.
  • Prostatype Genomics AB
  • Proteomedix AG
  • Siemens Healthineers AG
Product Code: MRR-A339DAEFAC09

The Prostate Cancer Diagnostics Market was valued at USD 1.27 billion in 2023, expected to reach USD 1.45 billion in 2024, and is projected to grow at a CAGR of 14.20%, to USD 3.23 billion by 2030.

The prostate cancer diagnostics market encompasses a range of tests and technologies used to identify and monitor prostate cancer in patients. This involves traditional methods like PSA (prostate-specific antigen) tests and biopsies, as well as advanced procedures including MRI and genomic testing. The necessity of efficient diagnostic tools is evident due to the prevalence of prostate cancer, particularly in aging populations, making accurate diagnosis crucial for effective treatment and management. Applications extend into early detection, monitoring disease progression, and evaluating treatment efficacy. End-users include hospitals, diagnostic laboratories, and cancer treatment centers.

KEY MARKET STATISTICS
Base Year [2023] USD 1.27 billion
Estimated Year [2024] USD 1.45 billion
Forecast Year [2030] USD 3.23 billion
CAGR (%) 14.20%

Market growth is primarily driven by increasing incidences of prostate cancer, technological advancements, and rising awareness about the disease. Personalized medicine and biomarker tests present significant opportunities, focusing on enhancing diagnostic accuracy and patient-specific treatment plans. The integration of artificial intelligence in diagnostic tools also shows promise, potentially improving detection rates and reducing interpretation time. Investment in research and development to enhance the sensitivity and specificity of diagnostic tools will likely yield significant gains for industry players. Notably, emerging markets with developing healthcare infrastructures offer untapped potential for expansion.

However, challenges persist, such as high costs associated with advanced diagnostic technologies and a lack of adequate healthcare infrastructure in underdeveloped regions. Additionally, the potential for false positives in standard diagnostic methods could lead to unnecessary procedures, emphasizing a need for more precise and reliable tests. Regulatory hurdles and the lengthy approval processes also pose barriers to market entrants and innovations.

Innovations focusing on non-invasive testing methods, such as liquid biopsies and multi-parametric imaging, represent promising avenues for research. Moreover, the use of big data and machine learning to analyze patient data for pattern recognition will provide insights contributing to early diagnosis and personalized treatment strategies, further driving market growth. To leverage these opportunities, companies should invest in technology advancements and strategic partnerships to increase their market share and influence.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Prostate Cancer Diagnostics Market

The Prostate Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising aging population and increasing prevalence rate of prostate cancer
    • Growing government's initiatives for advancement in technology in diagnosis and creating awareness regarding cancer
  • Market Restraints
    • Stringent regulations and high cost of diagnosis
  • Market Opportunities
    • Innovation in drugs and developments in genomics and proteomics
    • Imaging research and advancements for accurate detection of prostate cancer
  • Market Challenges
    • Low success rate of clinical trials

Porter's Five Forces: A Strategic Tool for Navigating the Prostate Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Prostate Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Prostate Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Prostate Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Prostate Cancer Diagnostics Market

A detailed market share analysis in the Prostate Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Prostate Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Prostate Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Prostate Cancer Diagnostics Market

A strategic analysis of the Prostate Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Prostate Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, bioMerieux SA, Eurolyser Diagnostica, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Hologic, Inc., Koninklijke Philips N.V., mdxhealth BV, Myriad Genetics, Inc., OPKO Health, Inc., Prostatype Genomics AB, Proteomedix AG, and Siemens Healthineers AG.

Market Segmentation & Coverage

This research report categorizes the Prostate Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Confirmatory Tests and Preliminary Tests. The Confirmatory Tests is further studied across Biopsy, PCA3 Tests, and Trans-Rectal Ultrasound.
  • Based on Age Group, market is studied across Age 55-75, Age 75.
  • Based on End-User, market is studied across Cancer Research Institutes, Hospital Associated Laboratories, and Independent Diagnostic Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population and increasing prevalence rate of prostate cancer
      • 5.1.1.2. Growing government's initiatives for advancement in technology in diagnosis and creating awareness regarding cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations and high cost of diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovation in drugs and developments in genomics and proteomics
      • 5.1.3.2. Imaging research and advancements for accurate detection of prostate cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Low success rate of clinical trials
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Prostate Cancer Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Confirmatory Tests
    • 6.2.1. Biopsy
    • 6.2.2. PCA3 Tests
    • 6.2.3. Trans-Rectal Ultrasound
  • 6.3. Preliminary Tests

7. Prostate Cancer Diagnostics Market, by Age Group

  • 7.1. Introduction
  • 7.2. Age 55-75
  • 7.3. Age < 55
  • 7.4. Age > 75

8. Prostate Cancer Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Research Institutes
  • 8.3. Hospital Associated Laboratories
  • 8.4. Independent Diagnostic Laboratories

9. Americas Prostate Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Prostate Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Prostate Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AdvaCare Pharma
  • 2. bioMerieux SA
  • 3. Eurolyser Diagnostica
  • 4. Exact Sciences Corporation
  • 5. F. Hoffmann-La Roche AG
  • 6. Hologic, Inc.
  • 7. Koninklijke Philips N.V.
  • 8. mdxhealth BV
  • 9. Myriad Genetics, Inc.
  • 10. OPKO Health, Inc.
  • 11. Prostatype Genomics AB
  • 12. Proteomedix AG
  • 13. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. PROSTATE CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PROSTATE CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PROSTATE CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCA3 TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TRANS-RECTAL ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRELIMINARY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE 55-75, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE <55, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE>75, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITAL ASSOCIATED LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023